MARKET

CYCC

CYCC

Cyclacel Pharma
NASDAQ
0.3038
+0.0185
+6.48%
After Hours: 0.2438 -0.06 -19.75% 19:59 04/29 EDT
OPEN
0.2335
PREV CLOSE
0.2853
HIGH
0.4100
LOW
0.2280
VOLUME
109.60M
TURNOVER
--
52 WEEK HIGH
1.897
52 WEEK LOW
0.0809
MARKET CAP
74.84M
P/E (TTM)
-0.1451
1D
5D
1M
3M
1Y
5Y
1D
Tuesday Sector Leaders: Cigarettes & Tobacco, Drugs
NASDAQ · 12h ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 16h ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 1d ago
Weekly Report: what happened at CYCC last week (0421-0425)?
Weekly Report · 1d ago
Cyclacel Pharmaceuticals files to sell 35.18M shares of common stock for holders
TipRanks · 4d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 4d ago
Cyclacel Pharmaceuticals declares $0.15 dividend
Seeking Alpha · 4d ago
Cyclacel Pharmaceuticals Has Been Granted European Patent Number EP4013503 Titled "CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE (FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUCH AS CANCER, LEUKAEMIA, AND LYMPHOMA)".
Benzinga · 5d ago
More
About CYCC
More
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
Recently
Symbol
Price
%Change

Webull offers Cyclacel Pharmaceuticals Inc stock information, including NASDAQ: CYCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYCC stock methods without spending real money on the virtual paper trading platform.